Peptide Reclassification: What Every Wellness Clinic Needs to Know

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced on the Joe Rogan Experience (Episode #2461) that approximately 14 of the 19 peptides placed on the FDA's Category 2 restricted list in 2023-2024 are expected to be reclassified back to Category 1 status. This announcement has significant implications for wellness clinics, functional medicine practices, and compounding pharmacies across the United States.

This briefing explains what happened, what it means in practical terms, and how your clinic should prepare — including important caveats about the distinction between a political announcement and formal regulatory change.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, the FDA evaluates bulk drug substances that compounding pharmacies wish to use. Substances are placed into one of three categories:

• Category 1: Substances that may be used in compounding while under evaluation. Eligible for compounding by licensed 503A and 503B pharmacies.
• Category 2: Substances identified as potentially presenting significant safety risks. Generally NOT eligible for compounding.
• Category 3: Substances that have not yet been evaluated.

Between late 2023 and 2024, the FDA placed 19 widely-used wellness peptides on the Category 2 "do not compound" list, citing concerns about immunogenicity (immune reactions), manufacturing impurities, and insufficient large-scale human clinical trial data. The move was widely criticized by integrative medicine practitioners, compounding pharmacies, and patient advocacy groups who argued the FDA had acted without an adequate safety signal — which is legally required before placing substances in Category 2.

In response to the controversial Category 2 designations, the Alliance for Pharmacy Compounding (A4PC) filed suit against the FDA, arguing the agency lacked the required safety signal to justify the restrictions.

Result: In September 2024, the FDA agreed to a settlement, committing to submit several key peptides for review by the Pharmacy Compounding Advisory Committee (PCAC) — including Ipamorelin (reviewed October 29, 2024), and CJC-1295, AOD-9604, and Thymosin Alpha-1 (reviewed December 4, 2024).

This forced the FDA to follow proper notice-and-comment rulemaking before permanently restricting these compounds — a significant procedural victory for the compounding and wellness community.

The restrictions did not eliminate demand for peptides — they redirected it. With licensed compounding pharmacies unable to legally fill prescriptions, a "research use only" gray market expanded dramatically. Patients and some clinics began sourcing peptides from unregulated online vendors, raising serious concerns about:

• Contamination and lack of sterility testing
• Incorrect dosing and mislabeling
• No USP 797/795 compliance
• Complete absence of quality control

Secretary Kennedy directly acknowledged this unintended consequence during the Rogan interview, stating the restrictions effectively "created the gray market." This public health argument became a central rationale for revisiting the classifications.

During his appearance on the Joe Rogan Experience, Secretary Kennedy stated that he intends to move approximately 14 of the 19 Category 2 peptides back to Category 1 status, and that a formal FDA announcement could come within weeks of the recording. He characterized the original Category 2 classifications as having been made without legitimate safety signals and described the restrictions as overreach.

As of the date of this publication, NO formal FDA rule has changed. Specifically:

• No Federal Register notice has been issued removing peptides from Category 2
• No statute has been amended
• No formal FDA announcement has been published

Kennedy's remarks reflect policy intention, not current regulatory reality. The Secretary of HHS has influence over FDA policy direction but cannot unilaterally rewrite federal drug law. Formal regulatory change requires one of: (1) a published Federal Register notice, (2) a PCAC review and recommendation, (3) Congressional action, or (4) a formal FDA enforcement discretion policy.

Clinics that resume compounding restricted peptides prior to formal FDA action do so at legal risk.

Based on available regulatory analysis and the PCAC review process already underway, here is the current status picture for the 19 peptides that were placed in Category 2:

Note: The above reflects analyst expectations based on publicly available information as of March 2026. Official FDA classifications are subject to change. Approximately 5 peptides are expected to remain in Category 2 due to stronger safety concerns or limited human data.

If and when formal Category 1 reclassification occurs for these 14 peptides, the practical effects for wellness clinics will be significant:

While awaiting formal reclassification, clinics should understand that enforcement risk has escalated substantially since 2024. A comprehensive review of federal and state enforcement activity through early 2026 documents actions including:

• A $300,000 settlement in Connecticut involving a clinic dispensing Category 2 peptides
• An asset freeze and clinic closure in Alabama (State of Alabama v. Aurora IV & Wellness, LLC)
• Medical board cease-prescribing directives in Mississippi targeting peptide prescribers
• License suspensions in Ohio based solely on the presence of research-labeled peptide vials on premises

State attorneys general have deployed consumer protection statutes, deceptive trade practice laws, and public health authority — theories that are portable across state lines. Importantly, malpractice insurance frequently excludes claims involving unapproved drug use, creating compounding liability exposure for clinic owners.

The following steps are appropriate regardless of when or whether formal FDA action occurs:

• Conduct a peptide audit. Inventory all peptides currently offered, prescribed, or on-premises. Classify each as Category 1, Category 2, or unclassified. Remove any research-labeled peptides from clinical use immediately.
• Review your malpractice coverage. Contact your malpractice insurer to confirm whether your policy covers administration of compounded or unapproved drug substances. Document the response in writing.
• Consult a healthcare regulatory attorney. Before resuming any peptide offerings — or modifying your current practice — seek specific legal guidance for your state. Enforcement approaches vary by jurisdiction.
• Establish compounding pharmacy relationships. Begin or renew relationships with licensed 503A compounding pharmacies now, so you are positioned to pivot quickly when formal reclassification occurs.
• Educate your patients. Patients following this news may ask about availability. Communicate clearly that the announcement represents regulatory intent, not current law, and that your clinic will resume peptide offerings only through fully compliant, licensed channels.
• Monitor the FDA Federal Register. Subscribe to FDA compounding updates at fda.gov/drugs/human-drug-compounding. Formal reclassification will be published there before it takes effect.

Once the FDA publishes a formal rule or enforcement policy, clinics should take the following additional steps before resuming clinical use of reclassified peptides:

• Verify your compounding pharmacy's Certificate of Analysis (CoA) and USP 797 compliance for each reclassified peptide
• Update your informed consent documents to reflect the current regulatory status and evidence base for each peptide
• Establish monitoring and follow-up protocols — reclassification is not FDA approval; ongoing clinical oversight remains essential
• Train clinical staff on proper storage, handling, and reconstitution per compounding pharmacy guidelines
• Document clinical rationale in patient records for each peptide prescribed

The potential reclassification of approximately 14 peptides from Category 2 to Category 1 represents the most significant positive regulatory shift for the peptide therapy field since the original restrictions took effect. For wellness clinics that have been navigating patient demand against legal risk, this development — when formalized — should substantially expand the toolkit available through safe, compliant channels.

However, the peptide landscape will continue to evolve. Regulatory analysts note that some reclassified peptides could eventually seek full FDA approval and pharmaceutical patent protection. Should that occur, compounding access could again be curtailed for those specific compounds. Staying informed and maintaining flexible, compliant practice structures will be essential.

The overarching message from this regulatory episode is clear: peptide therapy is most effective and most defensible when delivered under physician supervision, through licensed pharmacies, with documented clinical rationale and patient monitoring. That principle holds regardless of how the regulatory landscape continues to shift.

• FDA Compounding Updates: fda.gov/drugs/human-drug-compounding
• Alliance for Pharmacy Compounding (A4PC): a4pc.org
• Pharmacy Compounding Advisory Committee (PCAC) meeting minutes: fda.gov/advisory-committees
• Federal Register (search: "bulk drug substances compounding"): federalregister.gov

This document is provided for informational and educational purposes only. It does not constitute legal or medical advice. Clinics should consult qualified legal counsel before modifying their peptide therapy offerings in response to regulatory changes.